ArticleReviews in cardiovascular medicine2025
Glomerular Filtration Rate by Differing Measures in Predicting Atrial Fibrillation Recurrence After Ablation.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Significant differences often exist between estimated glomerular filtration rates (eGFR) calculated using various biomarkers. However, the relationship between these eGFR methods and atrial fibrillation (AF) recurrence after radiofrequency catheter ablation (RFCA) remains unclear. Methods: Thus, this study employed a retrospective analysis of 523 patients with AF who underwent an initial RFCA between July 2019 and October 2022. The eGFR was calculated using three methods based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula: serum creatinine (eGFRcr), serum cystatin C (eGFRcys), and a combination of both (eGFRcrcys). Cox regression models were used to explore the relationship between eGFR and AF recurrence. Results: Over a 1-year follow-up period, 174 (33.3%) patients experienced AF recurrence after RFCA. Multivariable Cox regression analysis indicated that only eGFRcys showed a consistent, significant inverse association with AF recurrence (hazard ratio (HR) = 0.990, 95% confidence interval (CI): 0.982-0.998, Conclusions: The association between eGFR and AF recurrence after ablation appears to vary depending on the measurement methods; eGFRcys seems to provide the most reliable information. Incorporating eGFRcys into the pre-ablation risk stratification may enhance patient management and improve outcomes for patients undergoing AF ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.